Tailored treatment of prostate cancer by biomarkers: PROCABIO

Tailored treatment of prostate cancer by biomarkers: PROCABIO - PROCABIO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33361

Enrollment

Registered

2009-03-26

Start date

2010-02-02

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer Prostate carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who decide to participate in PRIAS or are participating in PRIAS for less than 2 years are eligible. The inclusion criteria for PRIAS are the following: 1. Histologically proven adenocarcinoma of the prostate 2. Men should be fit for curative treatment 3. PSA-level at diagnosis

Exclusion criteria

Exclusion criteria: The exclusion criteria for PRIAS are the following: 1. Men who can not or do not want to be irradiated or operated 2. A former therapy for prostate cancer

Design outcomes

Primary

Measure	Time frame
Results of the analysis of the candidate biomarkers in the appropriate type of sample in the patient sample sets from all clinical centres.	—

Secondary

Measure	Time frame
N.a.	—

Countries

Netherlands

Outcome results